Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Florida. Details of the presentations are as follows: Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial Abstract Number: 12336 Session C96: Lung-Specific Immunity in Viral Infection: From Real-Time Host Responses to Novel Antiviral Strategies Session Type: Mini Symposium Date and Time: Tuesday, May 19, 2026, from 2:15 PM – 2:27 PM EDT Presenter: Christopher Harris, M.D. Title: EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model Poster Number: P72 Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies Session Type: Thematic Poster Session Date and Time: Tuesday, May 19, 2026, from 11:30 AM – 1:15 PM EDT Presenter: Yaohui Nie, Ph.D. Title: EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma Poster Number: P75 Session Type: Thematic Poster Session Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies Date and Time: Tuesday, May 19, 2026, from 11:30 AM – 1:15 PM EDT Presenter: Lisha Xu and Yang Li, Ph.D. Further information about ATS 2026 can be found here. Presentations will be available on the Company’s website here following each presentation. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20260504237451/en/ Media and Investors: Jennifer Viera 617-744-3848 [email protected] Source: Enanta Pharmaceuticals, Inc. Print Page Print Page Email Alerts Email Alerts RSS Feeds RSS Feeds Contact IR Contact IR ©2026 Enanta Pharmaceuticals, Inc. ENANTA PHARMACEUTICALS and accompanying logos are trademarks or registered trademarks of Enanta Pharmaceuticals, Inc. Explore About Pipeline Science Patients Careers Collaborations Investors Contact Us Contact Enanta Pharmaceuticals, Inc. Headquarters 4 Kingsbury Avenue Watertown, MA 02472 (617) 607-0800 [email protected] Legal Privacy Policy Terms of Use Twitter Linkedin MENU About About Us Management Team Board of Directors Timeline Pipeline Overview Hepatitis C Virus Hepatitis B Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology Science Overview Publications Patients Overview Clinical Trials Expanded Access Policy Resources Careers Join Us Culture Core Values Testimonials Benefits Collaborations Partnering Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feeds Email Alerts Contact Us

The release as fetched from its publisher. enanta.com ↗